Table 4.

Number of events, crude and standardised incidence rates and HR for all cancers other than NMSC and NMSC, in Swedish patients with PsA treated with JAKi

Cohort	Events	Crude incidence rate per 1000 person-years	Standardised incidence rate per 1000 person-years	Fully adjusted HR*
All cancers other than NMSC
JAKi	5	8.6	7.3	1.88 (0.68 to 5.16)
Non-TNFi	2	4.8	–	–
TNFi	73	5.8	5.8	1.0 (Reference)
Gen population	317	5.9	6.0	n/a
NMSC
JAKi	8	13.9	11.7	2.05 (0.79 to 5.31)
Non-TNFi	2	4.8	–	–
TNFi	73	5.8	5.8	1.0 (Reference)
Gen population	209	3.9	3.9	n/a

Non-TNFI includes rituximab, abatacept and tocilizumab. Estimated from proportional hazards Cox regression models. Standardised incidence rate standardised to the age- and sex distribution in the TNFi cohort. – is displayed when too few events (<5) were observed.

*Fully adjusted HR: adjusted for age, sex, line of therapy, for comorbidities, SES, disease-related factors and with missing categories included for those variables with missing information.

JAKi, Janus kinas inhibitor; n/a, not available; NMSC, non-melanoma skin cancer; PsA, psoriatic arthritis; SES, socioeconomic status; TNFi, tumour necrosis factor inhibitor.